Almirall, S A : Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
BARCELONA, February 19, 2024 Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its full-year 2023 financial results.
Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseasesNN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated diseases BARCELONA, Spain (BU.